UCB - Sales Revenues

Stock Price
260.60
Daily Change
5.20 2.04%
Monthly
10.94%
Yearly
40.26%
Q1 Forecast
249.19

UCB reported EUR3.49B in Sales Revenues for its fiscal semester ending in June of 2025.





Sales Change Date
Alcon AG USD 2.59B 10M Sep/2025
Almirall EUR 560.46M 71.95M Jun/2025
Amarin USD 49.67M 23.07M Sep/2025
argenx SE USD 987.09M 144.59M Sep/2025
AstraZeneca USD 15.19B 733M Sep/2025
Bayer EUR 9.66B 1.08B Sep/2025
Galapagos EUR 65.3M 4.87M Sep/2025
Genmab DKK 5.86B 580M Jun/2025
GlaxoSmithKline GBP 8.55B 557M Sep/2025
GRIFOLS EUR 1.87B 20M Sep/2025
Hikma Pharmaceutical USD 829M 758M Jun/2025
Lonza CHF 3.58B 63M Jun/2025
Merck EUR 5.32B 890M Sep/2025
Novartis USD 13.91B 144M Sep/2025
Orion EUR 423.2M 6.7M Sep/2025
Recordati EUR 624.35M 18.8M Sep/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sanofi EUR 11.3B 1.13B Dec/2025
UCB EUR 3.49B 129M Jun/2025
Unibail Rodamco EUR 1.57B 357.7M Jun/2025